The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
COdey, but all shares go up, don't they? ;)
The trouble with buying the shares outright rather than via the Placing is that I'm likely to pay around 20% - 33% more. (That's assuming the Placing share price will be 6p, and the regular share price will maintain around 8p - 10p.) Another option is to wait and see if the share price drops to the Placing price and just buy them into my ISA account then. But it might not drop that low.
I'm considering buying some Placing shares. I called PrimaryBid.com and apparently the Placing shares can only go into a regular non_ISA share account. That's a shame, as I would then be liable for capital gains tax later.
Does anyone know if this is normal for Placing shares?
This is a bit unusual - the RNS this morning seemed quite positive; a 5-year contract yilding $10m (5% of annual revenue) per year. The share price rose, then dropped significantly. What would explain that drop?
This stock has done extremely well so far this year, acording to share price. I am very curious to see how the final results look.
But I do note that in the RNS on 9 Apr, they expected the full year's revenue to be £200m. That is less than half of their annual revenue for the last 4 years. Given that reduction, why the optimism and increase in share price?
Superb results! I just wish I'd bought in on 7 May on the RNS back then! All signs were positive. The question now is how much higher could this go? The profits have doubled, but the share price has also now doubled from May to now (~400p to ~820p). So for me, I think I might have missed the boat. Oh well, lesson learned.
Regarding the Special Dividend on 20p announced today - this alone would warrant a 2.5% increase is share price.
philjpo, can you post a link to the RNS that you're referring to, please? I don't see any RNS on 18th Feb relating to the CE Mark.
However, there is an RNS on 17th Feb that states they have launched their CE Marked test - but that RNS does not state the date the CE Mark was actually recevied.
I cannot find an RNS from NCYT that states the date on which the CE-Mark was received. From what I can gather, it occurred in early February. If someone knows the exact date, please post the link.
In any case, my overall point is this: NCYT was able to receive significant sales and orders for their product while GDR still cannot even say they are in discussions with potential customers. This is not what one would expect if GDR's product is indeed the "gold standard" and "best of class" as has been claimed. It just doesn't stack up.
On the point that NCYT's test only looks at 1 gene - does anyone know whether GDR's test looks at more than 1 gene? A link to that info would be useful.
So, in summary:
NCYT has already sold £120m of its product, and was able to take orders BEFORE it received the CE Mark.
In contrast, it has been 3 weeks since GDR received the CE Mark; yet GDR still hasn't reported a single sale, let alone any interest in it's product or any quotation requests.
oops, accidentally posted message before finished.
NYCT
6 Apr: Reports approval for distribution of its test into France and Thailand
27 Apr: Reports contract with UK Department of Health for 233,000 tests per week.
2 Jun: Reports total sales as of 1 Jun is £120m.
I watched the investor presentation yesterday and was struck by the seeming avoidance of Budd to discuss orders fo r the product in a normal way. I decided to go back through the RNS releases of both GDR and NCYT to compare the companies.
GDR
25 Mar: Announces a SARS-CoV-2 test in development could be ready in 8 weeks. No mention of orders, quotation requests, or interest in its test.
20 Apr: Announced agreement with Cytiva in development of its test. No mention of orders, quotation requests, or interest in its test. An no mention of financial details of this agreement (does Cytiva get a proportion of any of GDR's sales?)
1 May: Announced milestones achieved. No mention of orders, quotation requests, or interest in its test.
22 May: Received CE Mark for its test. Still no mention of orders, quotation requests, or interest in its test; though the RNS mentions "The Company will now begin distribution to *potential* customers" and expects sales in June.
11/12 June Investor presentation is announed. Still no mention of any orders, quotation requests, or interest in its test. When asked about sales, Budd explains "We only just received CE Mark 3 weeks ago. Our customers need time to check that our test works before they buy".
NCYT
On 31 Jan: NCYT launched their coronavirus test. Their test is stable at room temperature and does not require any refridgeration or cooling technology.
7 Feb NCYT report £33k in sales, plus £32k in requests for quotes. This was *before* receiving a CE-Mark.
14 Feb: Is taking more orders for their test which is planned to receive a CE-Mark shortly.
28 Feb: Almost £1m sales reported, and a high level of interest from potential customers, plus requests for more quotes.
30 Mar: Reports sales of over £17m, with demand increasing; mentions working with a number of UK hospitals.
6 Apr: Reports approval for
Very interesting. The share price closed at 3.51, yet opened this morning at 4.1, despite the RNS that a major Instutional Investor, Directional Opportunities Master Fund Limited, sold £2m.
The Terms of Transaction allow for ZOE to purchase up to 30,000,000 of PATH's shares, currently worth 0.7p each, at a cost of 1.5p each. This will be a good dead for ZOE when PATH's share price doubles.
The 5% royalties from DTU sales sounds reasonable, though.
On London Stock Exchange website, it says PATH has a Trading Status of "Suspended". What does this mean